Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $315
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.
Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.